Stem cells for a transplant are usually collected from the blood rather than the bone marrow. Daily injections of a growth factor for about four to five days move stem cells out of the marrow into the blood, and a machine then filters them out over a few hours while the rest of the blood is returned. If too few cells appear in the blood, a second medicine called plerixafor can be added.
The reader's own unit's policy comes first. Patients (autologous): G-CSF alone ('steady state', filgrastim 10 micrograms/kg/day under the skin, apheresis usually on day 5) for those needing no further chemotherapy, or chemotherapy plus G-CSF where tumour reduction or a high yield is needed (EBMT Handbook 2024); after chemotherapy the Handbook gives the approved filgrastim dose as 5 micrograms/kg/day, often rounded up to 5 to 10 in practice. The US filgrastim label gives 10 micrograms/kg/day for at least 4 days before the first apheresis and until the last. In myeloma, the US lenalidomide label says mobilisation should occur within 4 cycles of a lenalidomide-containing therapy. Monitor blood CD34 from day 4 to 5 of G-CSF at the latest, or when leucocytes recover after chemotherapy; start apheresis above 20 CD34 cells per microlitre. The Handbook gives the minimum dose for one autologous transplant as 2 million CD34 cells per kg (optimal 2.5 to 5 million) and for an allogeneic transplant 4 million per kg of the recipient (optimal 5 to 8 million). Poor mobilisation (about 15% of patients): the Handbook recommends plerixafor below 10 CD34 cells per microlitre on days 4 to 5, considers it between 10 and 20, and uses it as rescue if the first apheresis yields under a third of the goal; the US label sets no count threshold: plerixafor is indicated with filgrastim in non-Hodgkin lymphoma and myeloma, started after 4 days of filgrastim and given about 11 hours before each apheresis for up to 4 days, at 0.24 mg/kg (or a fixed 20 mg at 83 kg or less), not above 40 mg a day; when creatinine clearance is 50 mL/min or less the dose is reduced by one third to 0.16 mg/kg (or a fixed 13 mg at 83 kg or less) and should not exceed 27 mg a day. Motixafortide is a US-labelled alternative in myeloma. Donors (allogeneic): fitness is assessed by a physician who is not the patient's treating physician (WMDA 3.22.3.1); pregnancy test and haemoglobinopathy risk assessment before mobilisation (FACT-JACIE B6.3.5, B6.3.6); mobilising agents given under experienced supervision (B6.3.4); a central venous catheter only in exceptional, documented circumstances (WMDA 8.05.2); a session of no more than 5 hours and no more than two consecutive sessions (Handbook); follow-up contact for at least 10 years (WMDA 9.02). Plerixafor is not approved for healthy donors, and the US filgrastim label says mobilisation in healthy donors is not an approved indication. Left upper abdominal or shoulder pain during G-CSF needs assessment for splenic enlargement or rupture (label).
Why: This keeps the judgement about whether the donor is fit to donate separate from the care of the patient who is waiting for the cells.
“This examination must be performed or supervised by a physician who is not the primary treating physician overseeing the care of the patient.”
World Marrow Donor Association 2024 · Standard 3.22.3.1 (must)
Why: A pregnancy must be known about before any mobilising medicine is given. The filgrastim label warns that severe and sometimes fatal sickle cell crises can occur in people with sickle cell disorders given G-CSF.
“The donor shall be evaluated for the risk of hemoglobinopathy and, if indicated, tested.”
Foundation for the Accreditation of Cellular Therapy (FACT) and JACIE (ISCT and EBMT) 2025 · Standard B6.3.6 (shall)
Why: G-CSF alone has fewer side effects, a predictable collection day and can be given as an outpatient, but fails more variably and yields fewer cells; adding chemotherapy collects more cells and treats the cancer but brings the side effects of chemotherapy.
“Steady-state mobilization should be considered for patients who are not in need for chemotherapy due to the underlying disease (e.g., MM) or disease status (i.e., stable remission).”
Why: The filgrastim label lists bone pain, fever and headache as the most common side effects of mobilisation and warns of serious ones, so the person in charge needs to know what to look for.
“Administration of mobilization agents shall be under the supervision of a licensed health care professional experienced in the administration of these agents and management of complications in persons receiving them.”
Foundation for the Accreditation of Cellular Therapy (FACT) and JACIE (ISCT and EBMT) 2025 · Standard B6.3.4 (shall)
Why: Stem cells need several days of growth factor to reach the blood in useful numbers, and the injections carry on so the numbers hold up through the collection days.
“Administer NEUPOGEN for at least 4 days before the first leukapheresis procedure and continue until the last leukapheresis.”
Amgen (industry), on DailyMed, US National Library of Medicine 2026 · Prescribing information, section 2.3
Why: The spleen can enlarge during G-CSF and has ruptured, in some cases fatally; the label lists pain in the left upper abdomen or left shoulder as the symptoms and asks that they be reported immediately.
“Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture.”
Amgen (industry), on DailyMed, US National Library of Medicine 2026 · Prescribing information, section 5.1
Why: The Handbook calls the CD34 count in the blood before apheresis the most robust predictor of poor mobilisation, and says the peak after chemotherapy is hard to predict without daily counts.
“If not otherwise specified by the protocol, CD34 monitoring should be initiated at the latest if leukocytes increase up to 1000 μL during recovering from aplasia or at day 4–5 of G-CSF in steady-state mobilization.”
Why: The Handbook counts people who bring fewer than 20 CD34 cells per microlitre into the blood as poor mobilisers, for whom it says plerixafor should be considered.
“A start of leukapheresis is indicated when a CD34+ cell count of >20/μL is reached (Mohty et al. 2014).”
Why: Enough stem cells are needed for the blood counts to recover reliably after high-dose treatment.
“The target number of HSC to be collected is dependent among others on the kind of transplant (e.g., autologous or allogeneic), the stem cell source (BM or PB), and the underlying disease (Table 16.2).”
Why: The lenalidomide label reports fewer CD34 cells collected after more than 4 cycles. For people already past that point, or who collect too few with G-CSF alone, it says G-CSF with cyclophosphamide or with a CXCR4 inhibitor such as plerixafor may be considered.
“For patients who are auto-HSCT-eligible, hematopoietic stem cell mobilization should occur within 4 cycles of a REVLIMID-containing therapy”
Celgene Corporation (industry), on DailyMed, US National Library of Medicine 2023 · Prescribing information, section 2.1
Why: The Handbook says mobilisation after high-dose treatment has an increased risk of failure, so a later collection cannot be relied on.
“In these cases, it is essential to collect the required number of HSC before the first high-dose therapy since mobilization after high-dose therapy has an increased risk of failure.”
Why: Plerixafor releases stem cells into the blood by a different route from G-CSF, and the Handbook says a second attempt with G-CSF after a failure is usually less effective. Between 10 and 20 the Handbook leaves the decision to the disease and the treatment history.
“Plerixafor is recommended when the CD34+ is <10/μL on days 4–5 of mobilization with G-CSF alone.”
Why: The Handbook says a first collection this low carries a high risk that mobilisation will fail.
“Furthermore, if it is not possible to collect at least one-third of the collection goal with the first apheresis session, plerixafor should be applied as a rescue strategy because of high risk of mobilization failure (Mohty et al. 2014; Cheng et al. 2015).”
Why: The label gives an evening dose before the next day's collection, with filgrastim each morning. Its dose is 0.24 mg per kg (or a fixed 20 mg at 83 kg or less), not more than 40 mg a day. When creatinine clearance is 50 mL/min or less it is cut by one third to 0.16 mg per kg (or a fixed 13 mg at 83 kg or less) and should not exceed 27 mg a day.
“Administer Mozobil approximately 11 hours prior to initiation of each apheresis for up to 4 consecutive days.”
Sanofi (industry), on DailyMed, US National Library of Medicine 2025 · Prescribing information, section 2.1
Why: The Handbook says collection is preferentially through a vein in the arm, with a central line where necessary; the WMDA standards also require a policy that protects the safety of a donor who has one.
“The registry must have a policy concerning the use of a central venous catheter in donors to ensure that a central venous catheter is only used in exceptional circumstances. Those circumstances must be documented.”
World Marrow Donor Association 2024 · Standard 8.05.2 (must)
Why: These are the limits the Handbook sets for donors. For patients it says more than three consecutive sessions are futile in most cases, and that the goal is unlikely to be reached if it has not been by the third.
“In the allogeneic setting, the duration of one leukapheresis session should not exceed 5 h and two consecutive sessions.”
Why: The standard asks for the fallback to be written down in advance, as part of the policies that protect the health and safety of the donor and of the recipient.
“These policies must include the procedure to follow in case of failed mobilisation, including the potential to switch to a bone marrow collection if necessary.”
World Marrow Donor Association 2024 · Standard 8.05.1 (must)
Why: The standards require care for any condition related to the donation, straight afterwards and in the long term, and a way for the donor to raise a concern years later.
“The registry must have policies and procedures for the long-term follow-up and care of donors for conditions related to the HSC donation, including a mechanism for donors to contact the registry to report related medical concerns for a minimum of ten (10) years after donation.”
World Marrow Donor Association 2024 · Standard 9.02 (must)
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
Donor safety has the firmest footing: the requirements here are 'must' and 'shall' standards of the World Marrow Donor Association (2024) and FACT-JACIE (ninth edition, version 9.1), which registries and transplant programmes are accredited against. For mobilising patients there is no single graded guideline that could be read in full. The steps follow the EBMT Handbook (2024), a handbook of expert chapters that draws on the EBMT position statement of 2014, with doses and timings from the manufacturers' labels. Two positions on plerixafor are shown side by side: the Handbook's count-guided use (added only when the blood CD34 count or the first collection is low) and the US label, which sets no count threshold and starts plerixafor after 4 days of filgrastim in people with non-Hodgkin lymphoma or myeloma. On lenalidomide the US label and the IMWG consensus of 2009 (abstract) agree that cells should be collected within the first 4 cycles. The American guidance of 2014 (ASBMT) could be read as abstracts only, which state no thresholds or targets, so its positions on CD34 targets and pre-emptive plerixafor are not shown; this is a named gap, not agreement.
World Marrow Donor Association 2024 · Foundation for the Accreditation of Cellular Therapy (FACT) and JACIE (ISCT and EBMT) 2025 · EBMT (Springer; Sureda, Corbacioglu, Greco, Kröger and Carreras, editors). A handbook of expert chapters, not a graded guideline 2024 · EBMT (Bone Marrow Transplantation, Mohty et al.). Medical writing funded by an unrestricted grant from Sanofi (industry) 2014 · Sanofi (industry), on DailyMed, US National Library of Medicine 2025 · Amgen (industry), on DailyMed, US National Library of Medicine 2026 · Celgene Corporation (industry), on DailyMed, US National Library of Medicine 2023 · International Myeloma Working Group (Blood, Kumar et al.) 2009
Where it differs: The US label, written for people with non-Hodgkin lymphoma or myeloma, sets no blood count threshold for starting plerixafor: "Initiate Mozobil treatment after the patient has received filgrastim once daily for 4 days." The count-guided ('pre-emptive' or 'just-in-time') approach in the EBMT Handbook adds it only below a blood CD34 threshold or after a poor first collection.
Evidence: The Handbook: "If a patient has below 20 CD34+ cells/μL, plerixafor application should be considered." Between 10 and 20 it leaves the decision to disease and treatment history, and for people with known risk factors for poor mobilisation says pre-emptive use should be considered. It reports that plerixafor reduces the number of apheresis sessions needed and so the cost of mobilisation. The EBMT 2014 abstract supports measuring the CD34 count before apheresis to allow pre-emptive intervention; its full text could not be read, and its medical writing was funded by a grant from the maker of plerixafor.
Sanofi (industry), on DailyMed, US National Library of Medicine 2025 · EBMT (Springer; Sureda, Corbacioglu, Greco, Kröger and Carreras, editors). A handbook of expert chapters, not a graded guideline 2024 · EBMT (Bone Marrow Transplantation, Mohty et al.). Medical writing funded by an unrestricted grant from Sanofi (industry) 2014
Where it differs: Gives a dose of chemotherapy (often cyclophosphamide 2 g per square metre, or the person's planned lymphoma chemotherapy) followed by G-CSF, with daily CD34 counts as the blood recovers, instead of G-CSF alone.
Evidence: The Handbook's key point: "Mobilization with chemotherapy plus G-CSF is the preferred method for patients who will need decrease of tumor burden or who have to collect a high number of HSC." It lists the costs as chemotherapy toxicity, a hospital stay in most cases, marrow damage that may impair later mobilisation and higher cost, says relapse rates are comparable between the two strategies, and that 4 g per square metre of cyclophosphamide adds toxicity over 2 g.
Where it differs: A newer injection, 1.25 mg per kg under the skin, given once 10 to 14 hours before the first apheresis after 4 days of filgrastim, with a possible second dose before a third apheresis. The label requires premedication before every dose.
Evidence: US label only: "APHEXDA is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma." The label's safety data come from 92 patients given motixafortide and 42 given placebo, each with filgrastim, in the GENESIS study. It reports anaphylactic shock in 0.7% of patients given motixafortide in clinical studies and injection site reactions in 73% in GENESIS, and tells prescribers to premedicate every patient with an H1-antihistamine, an H2 blocker and a leukotriene inhibitor, to add a painkiller such as paracetamol, and to give it only where anaphylaxis can be treated at once. No guideline read compares it with plerixafor, and the EBMT Handbook chapter (2024) does not mention it.
BioLineRx (industry), on DailyMed, US National Library of Medicine 2026
Where it differs: Collects early in induction, and plans for plerixafor or chemotherapy with G-CSF in people who have had more than 4 cycles of lenalidomide or a daratumumab-containing induction.
Evidence: The US lenalidomide label: "A decrease in the number of CD34+ cells collected after treatment (> 4 cycles) with REVLIMID has been reported." It asks for early referral to a transplant centre, and says that after more than 4 cycles, or after an inadequate collection with G-CSF alone, G-CSF with cyclophosphamide or with a CXCR4 inhibitor may be considered. The IMWG consensus of 2009 (abstract only) recommends mobilisation "preferably within the first 4 cycles of initial therapy" for people treated with novel agents. The Handbook lists lenalidomide and daratumumab among the risk factors for poor mobilisation and says people given daratumumab in induction needed plerixafor significantly more often; it gives no number of cycles. The US daratumumab label says nothing about mobilisation.
Celgene Corporation (industry), on DailyMed, US National Library of Medicine 2023 · International Myeloma Working Group (Blood, Kumar et al.) 2009 · EBMT (Springer; Sureda, Corbacioglu, Greco, Kröger and Carreras, editors). A handbook of expert chapters, not a graded guideline 2024
Where it differs: Some centres aim for the Handbook's optimal range (2.5 to 5 million CD34 cells per kg for an autologous transplant) and process more than four times the person's blood volume in a session.
Evidence: The Handbook says higher yields have been associated with faster blood count recovery, shorter hospital stay and fewer transfusions, and advises: "It may be advantageous to collect cells in this range, if the mobilization status of the patient allows it without additional leukapheresis session." For allogeneic grafts it also reports a study in which very high doses went with more extensive chronic graft-versus-host disease (62% against 34% at 4 years above and below 8.3 million per kg, sibling transplants).
Where it differs: Adds plerixafor to G-CSF for a donor whose CD34 count stays low, outside the licence.
Evidence: The Handbook: "The use of plerixafor is not approved for allogeneic SCT." It puts mobilisation failure in healthy donors at an estimated 5% to 10% and cites studies in which adding plerixafor raised CD34 cells about three-fold. The WMDA standards require a failed-mobilisation procedure, including a possible switch to marrow collection, and do not name a drug. The WMDA published a separate statement on plerixafor in healthy donors in 2026, which could not be read; its position is not given here. The US filgrastim label adds that mobilisation in healthy donors is not an approved indication for filgrastim either, and reports bleeding into the lungs in donors.
EBMT (Springer; Sureda, Corbacioglu, Greco, Kröger and Carreras, editors). A handbook of expert chapters, not a graded guideline 2024 · World Marrow Donor Association 2024 · Sanofi (industry), on DailyMed, US National Library of Medicine 2025 · Amgen (industry), on DailyMed, US National Library of Medicine 2026 · World Marrow Donor Association (Transplantation and Cellular Therapy) 2026
Where it differs: A child may be asked to donate for a brother or sister, which no adult volunteer standard covers in full.
Evidence: FACT-JACIE: "A donor advocate shall be available to represent allogeneic donors who are minors or who do not have the capacity to give consent, as those terms are defined by Applicable Law." The EBMT Handbook's paediatric chapter: "Minors should only be recruited as HSC donors if no medically equivalent histocompatible adult is available for donation and if there is a reasonable likelihood that the recipient will benefit from the procedure." It adds that donors under 4 years have a higher risk of complications, including from central line placement before apheresis.
Foundation for the Accreditation of Cellular Therapy (FACT) and JACIE (ISCT and EBMT) 2025 · EBMT (Springer; Sureda, Corbacioglu, Greco, Kröger and Carreras, editors). A handbook of expert chapters, not a graded guideline 2024
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Donor fitness examined or supervised by a physician independent of the patient's care | Standard 3.22.3.1 (must) | World Marrow Donor Association 2024 |
| Pregnancy test and counselling before mobilising agents for donors of childbearing potential “Female donors of childbearing potential must have a pregnancy test and be counselled to avoid pregnancy during the workup stage before use of mobilising agents, collection or initiation of the recipient’s preparative regimen, whichever occurs first.” | Standard 3.22.3.2 (must) | World Marrow Donor Association 2024 |
| Upper age for unrelated donors selected to donate should not exceed 60 years “The upper age limit for prospective donors selected to donate haematopoietic stem cells should not exceed sixty (60) years.” | Standard 3.16.1 (should) | World Marrow Donor Association 2024 |
| Rationale for central venous access in a donor to be documented “If central venous access is required, the rationale shall be documented in the donor’s records.” | Standard C6.3.10 (shall) | Foundation for the Accreditation of Cellular Therapy (FACT) and JACIE (ISCT and EBMT) 2025 |
| Mobilisation appropriate to the disease and the donor “Appropriate mobilization shall be used for the disease being treated and for the donor being collected.” | Standard B6.3.4.1 (shall) | Foundation for the Accreditation of Cellular Therapy (FACT) and JACIE (ISCT and EBMT) 2025 |
| Plerixafor 'clearly indicated' below 10 CD34 cells per microlitre “Below 10 CD34+ cells/μL, the use of plerixafor is clearly indicated to avoid mobilization failure.” | Handbook advice (ungraded) | EBMT (Springer; Sureda, Corbacioglu, Greco, Kröger and Carreras, editors). A handbook of expert chapters, not a graded guideline 2024 |
| Measuring the blood CD34 count before apheresis identifies people at risk of a poor collection and allows pre-emptive rescue “Determination of the CD34+ cell count in PB before apheresis helps to identify patients at risk of poor PBSC collection and allows pre-emptive intervention to rescue mobilisation in these patients.” | Position statement (ungraded; abstract) | EBMT (Bone Marrow Transplantation, Mohty et al.). Medical writing funded by an unrestricted grant from Sanofi (industry) 2014 |
| Plerixafor is licensed (US) with filgrastim for autologous collection in non-Hodgkin lymphoma and myeloma “Mozobil is indicated in combination with filgrastim to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM).” | Prescribing information, section 1 | Sanofi (industry), on DailyMed, US National Library of Medicine 2025 |
| Plerixafor dose by weight (US label) “Less than or equal to 83 kg: 20 mg dose or select dose based on 0.24 mg/kg actual body weight.” | Prescribing information, highlights and section 2.1 | Sanofi (industry), on DailyMed, US National Library of Medicine 2025 |
| Plerixafor dose reduced by one third in moderate and severe renal impairment (US label) “Renal impairment: If creatinine clearance is ≤50 mL/min, decrease dose by one-third to 0.16 mg/kg.” | Prescribing information, highlights and section 2.3 | Sanofi (industry), on DailyMed, US National Library of Medicine 2025 |
| Filgrastim 10 micrograms per kg a day under the skin for mobilisation (US label) “The recommended dosage of NEUPOGEN for the mobilization of autologous peripheral blood progenitor cells (PBPC) is 10 mcg/kg/day given by subcutaneous injection.” | Prescribing information, section 2.3 | Amgen (industry), on DailyMed, US National Library of Medicine 2026 |
| Filgrastim is not approved (US) for mobilisation in healthy donors “The use of NEUPOGEN for PBPC mobilization in healthy donors is not an approved indication.” | Prescribing information, section 5 | Amgen (industry), on DailyMed, US National Library of Medicine 2026 |
| Collect early, preferably within the first 4 cycles, after novel agents in myeloma (IMWG 2009) “Specifically, we recommend early mobilization of stem cells, preferably within the first 4 cycles of initial therapy, in patients treated with novel agents and encourage participation in clinical trials evaluating novel approaches to stem cell mobilization.” | Consensus (ungraded; abstract) | International Myeloma Working Group (Blood, Kumar et al.) 2009 |
| Filgrastim is licensed (US) for mobilising autologous progenitor cells “NEUPOGEN is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis” | Prescribing information, section 1 | Amgen (industry), on DailyMed, US National Library of Medicine 2026 |
| An optimal mobilisation regimen has not been defined (ASBMT 2014) “However, an optimal stem cell mobilization regimen has not been defined.” | Guideline abstract (grades not read) | Biology of Blood and Marrow Transplantation (Duong et al.) 2014 |
Shares Apheresis (leukapheresis), Leukapheresis to collect T cells for CAR T-cell manufacture, Autologous stem cell transplant (high-dose therapy), Allogeneic stem cell transplantation.
Shares Lenograstim, Growth factors: G-CSF and febrile neutropenia prevention, Filgrastim (G-CSF).
Shares Motixafortide, Filgrastim (G-CSF).
Shares Plerixafor, Filgrastim (G-CSF).
Shares Plerixafor, Filgrastim (G-CSF).
Shares Anthony Nolan, World Marrow Donor Association (WMDA).